A New Treatment Option for Dry AMD Is Bringing Hope to Patients
Posted by: Delray Eye Associates
For many years, patients diagnosed with dry age-related macular degeneration (AMD) had limited treatment options available to help preserve their vision. Today, exciting advancements in retinal care are providing new opportunities for eligible patients to take a proactive approach to managing this condition.
Patients throughout Delray Beach, Boca Raton, and surrounding communities now have access to Valeda® Light Therapy, the first FDA-authorized photobiomodulation treatment designed to improve visual acuity in eligible patients with dry AMD.
Dry AMD is one of the leading causes of vision loss among adults over the age of 50. The condition affects the macula, the central portion of the retina responsible for detailed vision used for activities such as reading, driving, and recognizing faces. As the disease progresses, patients may experience blurred central vision, difficulty seeing in dim lighting, and challenges performing everyday tasks.
What makes Valeda® different is its non-invasive approach to treatment. Unlike injections or surgical procedures, Valeda® uses specialized light therapy known as photobiomodulation (PBM). The treatment delivers specific wavelengths of light to retinal tissue, helping support cellular function within the eye.
Treatment is performed in the office and typically takes only a few minutes per session. Patients do not require injections, anesthesia, or dilation during treatment and are able to resume their normal daily activities immediately afterward.
Clinical studies have demonstrated that many eligible patients treated with Valeda® experienced improvements in visual acuity and maintained visual function over time. While individual results may vary, the availability of an FDA-authorized treatment specifically designed for dry AMD represents an important advancement in retinal care.
Early diagnosis remains one of the most important factors in protecting long-term vision. Because dry AMD often develops gradually, many patients may not notice symptoms until vision changes have already occurred. Routine eye examinations and retinal evaluations play a critical role in identifying the condition and determining whether treatment options such as Valeda® may be appropriate.
Patients who have been diagnosed with dry AMD or who have concerns about changes in their vision should speak with a retina specialist to discuss their options. A comprehensive retinal examination can help determine whether Valeda® Light Therapy may be a suitable treatment based on an individual’s specific condition and visual needs.
Advances in technology continue to reshape the future of eye care, and the introduction of Valeda® offers new hope for many patients seeking to maintain their independence, protect their vision, and continue enjoying the activities that matter most.
Call us today to book your exam.
